Minerva Capital Research Solutions

Marksans Pharma

NSE: MARKSANSBSE: 524404
Compare with peers
₹ 304.75▲ 5.75 (+1.92%)28 Oct, 03:29 pm IST
Market cap
₹ 13,009 Cr.
P/E
25.1x
P/B
4.41x
52-week range
155 – 350.95
ROE
15%
ROCE
19%
Dividend yield
0.3%
Debt / equity
0.11
Sector
Pharmaceuticals & Biotechnology
Industry
Pharmaceuticals
Listed on
NSE, BSE

About

Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates under single business segment, namely Pharmaceuticals. It operates two manufacturing facilities in Goa and maintains two research and development centers, located in Goa and in Navi Mumbai. Its product portfolio spreads various therapeutic segments of the cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products include pain management, upper respiratory, digestive health, vitamins, minerals and supplements (VMS) and skin care products. Its prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Pharmaceuticals: 221 companies →

Marksans Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)25.1 against a typical 33.2: cheaper than most peers (1st = cheapest).83rd of 220
  • Sales growth+35.6% against a typical +15.6% from a year earlier.44th of 197
  • Profit growth+174.1% against a typical +18.9% from a year earlier.21st of 160
  • Share price, 3 months+15.2% against a typical −1.8%.45th of 200
  • Size₹ 13,008.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).36th of 199

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

High safety

Rated AA- by 2 agencies
AA-
DefaultRiskyModerateSafeVery safe
  • All agencies agree and none has raised a warning.
AgencyCurrent ratingOutlookAs of
CARECARE AA-Stable7 Oct 2026
India RatingsIND AA-; IND A1+Positive4 Jun 2026
Credit rating actions
RatingDetails
7 Oct 2026
Reaffirmed
CARE AA-—CARE₹ 255.75 Cr.
4 Jun 2026
Rating action
IND AA-—India Ratings₹ 195.75 Cr.
6 Oct 2025
Reaffirmed
CARE AA-—CARE₹ 255.75 Cr.

Board meetings

Results dates and other board meetings. Full calendar

Details
4 Nov 2026UpcomingFinancial ResultsTo consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026
12 Aug 2026Financial ResultsTo consider and approve the Unaudited Financial Results for the quarter ended Jun 30, 2026
26 May 2026Financial Results/DividendTo consider and approve Audited Standalone and Consolidated Financial Results and to consider recommendation of dividend if any, for the Financial Year ended March 31, 2026
5 Feb 2026Financial ResultsTo consider and approve the financial results for the quarter ended December 31, 2025
13 Nov 2025Financial ResultsTo consider and approve the financial results for the period ended September 30, 2025
12 Aug 2025Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2025
19 May 2025Financial Results/DividendTo consider and approve the financial results for the period ended March 31, 2025 and dividend

Share price

1Y change +71.08%
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales531586560591642682708620720754856841
Expenses417453450462495543582520576594661628
Operating Profit114133110128147139127100144161195213
OPM %21%23%20%22%23%20%18%16%20%21%23%25%
Other Income195171502815622203525
Interest235333366667
Depreciation182221202021232327242425
Profit before tax11411310012012514311677133151200207
Tax %26%26%23%26%22%27%22%24%26%25%25%23%
Net Profit8483788998105915899114149159
EPS in Rs1.841.841.731.962.132.3121.292.172.53.273.47

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
13%
5 Years
16%
3 Years
17%
TTM
20%
Compounded Profit Growth
10 Years
18%
5 Years
12%
3 Years
16%
TTM
48%
Stock Price CAGR
10 Years
23%
5 Years
36%
3 Years
42%
TTM
—
Return on Equity
10 Years
17%
5 Years
17%
3 Years
16%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
43.87%
0 pts in a year
FIIs
17.47%
−2.42 pts in a year
DIIs
6.19%
+0.69 pts in a year
Public
32.46%
+1.72 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 25.1xEPS (12 months) ₹ 11.40Median P/E 23.3x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Marksans Pharma₹ 304.75₹ 13,009 Cr.25.1x4.4x15%—
Sun Pharmaceutical Industries₹ 1,743.00₹ 4,18,194 Cr.38.4x5.6x14.2%19.1%
Divi's Laboratories₹ 8,984.00₹ 2,38,497 Cr.73.3x11.5x16.2%24.3%
Torrent Pharmaceuticals₹ 4,482.00₹ 1,70,475 Cr.72.7x19.2x27.1%15.3%
Cipla₹ 1,337.00₹ 1,08,011 Cr.27.6x3.3x11.8%13.7%
Zydus Lifesciences₹ 1,127.85₹ 1,12,503 Cr.21.2x4.2x19.7%18.5%

Management

Mark B. Saldanha
Executive Chairman of the Board, Managing Director
Jitendra Sharma
Group Chief Financial Officer
Harshavardhan Panigrahi
Company Secretary, Compliance Officer
Sathish Kumar
Managing Director - UK Operations
David Mohammed
Managing Director - Australia Operations
Varddhman Vikramaditya Jain
Whole Time Director
Sandra Saldanha
Whole Time Director
Anjani Kumar
Chief Operating Officer - US Operations

Prices are delayed and for information only. Nothing on this page is investment advice.